CP and Parkinson disease: One way of addressing this issue involves comparing the ability of moderate iron chelation treatment to reducing both SN iron levels and United Parkinson’s Disease Rating Scale (UPDRS) scores in PD patients according to the level of ceruloplasmin activity.